Clinical trials: Hormone Refractory Prostate Cancer
Hormone Refractory Prostate Cancer
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer
The aim of this study is to evaluate efficacy and safety of Dovitinib(TKI258) in patients with castration resistant prostate cancer after failure of docetaxel-based chemotherapy.
- Trial name
- NCT01741116
- Testing
- TKI258
- Where
- 2 sites in South Korea
- Volunteers
- 44 people
- Sponsor
- Korean Cancer Study Group
Prostate Cancer, Hormone Refractory Prostate Cancer
A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
This is a multi-center open-label dose-escalation study of a novel compound (MDV3100) to treat patients with castration-resistant (hormone-refractory) prostate cancer.
- Trial name
- NCT00510718
- Testing
- MDV3100
- Where
- 9 sites in United States
- Volunteers
- 140 people
- Sponsor
- Pfizer
Hormone Refractory Prostate Cancer
Radiotherapy vs Observation for CRPC
The purpose of the study is to determine whether radiotherapy improves cancer control and overall survival among patients with Castration resistant prostate cancer.
- Trial name
- NCT01590498
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Zhengzhou University